Trump says Iran war "close to over" amid hopes for more negotiations
Liquidia Corp (NASDAQ:LQDA) Chief Business Officer Jason Adair sold 7,301 shares of common stock on April 13, 2026, at a price of $38.37, for a total value of $280,139. The sale was executed under a Rule 10b5-1 trading plan adopted on December 15, 2023.The transaction comes as Liquidia shares have surged 181% over the past year, currently trading at $38.71 with a market capitalization of $3.41 billion. According to InvestingPro analysis, the stock remains undervalued relative to its Fair Value, with earnings results due May 7. Investors can access 12 additional ProTips and comprehensive analysis through the detailed Pro Research Report available for LQDA.
On April 10, 2026, Adair also acquired shares of Liquidia Corp common stock through the conversion of restricted stock units and performance stock units. Specifically, 3,906 shares were acquired through restricted stock units, 2,474 shares through performance stock units, and 3,868 shares through performance stock units.
In other recent news, Liquidia Technologies reported its fourth-quarter 2025 earnings, showing a mixed financial performance. The company’s revenue exceeded expectations, driven by the strong launch of its Yutrepia drug, which recorded $90.1 million in revenue, marking a 74% growth quarter-over-quarter. However, despite this impressive revenue growth, earnings per share fell short of projections. Analysts have responded positively to the company’s recent developments. H.C. Wainwright raised its price target for Liquidia to $55, citing strong earnings and a shift towards profitability. BTIG also increased its price target to $50, highlighting the successful Yutrepia launch. Raymond James maintained a Strong Buy rating with a $47 target, noting Yutrepia’s performance is on par with Tyvaso DPI’s early launch. BofA Securities reiterated a Buy rating with a $44 target, emphasizing Liquidia’s competitive edge in the prostacyclin treatment space.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.